First, regarding KRAS mutation, the efficacy of cetuximab is associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors [23]. This evidence concerns the gene KRAS and colorectal cancer.